Organization
Hospital General Universitario Gregorio Marañón
5 abstracts
Abstract
Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry.Org: Instituto Valenciano de Oncología (IVO), GEICAM Spanish Breast Cancer Group, Hospital Universitario de Donostia-BioDonostia, Complejo Hospitalario Universitario a Coruña (CHUAC), Hospital Universitario de Canarias,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,
Abstract
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.Org: Hospital Universitario San Pedro de Alcántara, Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitari Vall d’Hebron y Vall Hebrón Institute of Oncology (VHIO),
Abstract
ASSOCIATION BETWEEN DISEASE ACTIVITY AND DAMAGE IN IDIOPATHIC INFLAMMATORY MYOPATHIES. DIFFERENCES BETWEEN INCIDENT AND PREVALENT CASESOrg: Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain, Hospital del Mar, Barcelona, Spain,